Literature DB >> 7140805

Modification in the pharmacokinetics of amikacin during development.

J M Lanao, A Dominguez-Gil, A A Dominguez-Gil, S Málaga, M Crespo, F Nuño.   

Abstract

The disposition kinetics of a single i.v. dose of amikacin was studied in 6 neonates (6-25 days old), 10 infants (4-18 months) and 8 young children (3-11 years). There was a progressive change in the distribution and elimination kinetics during development. The distribution coefficient of the antibiotic averaged of 0.429, 0.320 and 0.210 l/kg in the newborns, infants and young children, respectively and serum half-life (t1/2 beta) in these three groups averaged 2.812, 1.803 and 1.196 h, respectively. Significant differences in certain pharmacokinetic parameters were found between the values in paediatric patients and in adults receiving the same dose. A linear relationship was established between the distribution volume of the antibiotic and the weight of the patients, as defined by the following equation: Vdss (1) = 0.976 + 0.140 . TBW (kg); r = 0.954. The results suggest that a regimen of very frequent administrations should be employed in infants and young children in order to maintain a therapeutic level throughout treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140805     DOI: 10.1007/bf00545971

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Pharmacological evaluation of amikacin in neonates.

Authors:  J B Howard; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

2.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

3.  Distribution of amikacin in serum, muscle, and fat in children after a single intramuscular injection.

Authors:  F Daschner; E Reiss; J Engert
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum of infants.

Authors:  M G Myers; R J Roberts; N J Mirhij
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

5.  [Amikacin in the child: efficacy, tolerance, effects on the intestinal microbial ecosystem].

Authors:  H Mathieu; N Lambert-Zechovsky; F Beaufils; C Blum; E Binger; M Guillot
Journal:  Nouv Presse Med       Date:  1979-10-31

6.  [Kinetics of amikacin blood levels in neonates (author's transl)].

Authors:  A Olivesi
Journal:  Therapie       Date:  1979 Jul-Aug       Impact factor: 2.070

Review 7.  Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications.

Authors:  P L Morselli; R Franco-Morselli; L Bossi
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

8.  Influence of the route of administration on the pharmacokinetics of amikacin.

Authors:  J M Lanao; A Dominguez-Gil; J M Tabernero; L Corbacho
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Pharmacokinetics of dibekacin in young adult and geriatric patients.

Authors:  J M Lanao; A Dominguez-Gil; C Muriel; J Bueso
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

10.  A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing.

Authors:  W E Evans; R H Taylor; S Feldman; W R Crom; G Rivera; G C Yee
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

View more
  2 in total

Review 1.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.